Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant
Conclusion: TKI discontinuation outside of HSCT in Ph-positive ALL in the setting of compelling toxicity may be safe only among a highly selected group of patients with deep and prolonged DMR undergoing close and frequent monitoring. Validation of these findings in prospective clinical trials is highly needed.Acta Haematol
Source: Acta Haematologica - Category: Hematology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Chemotherapy | Clinical Trials | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Toxicology | Transplants